Eur Rev Med Pharmacol Sci 2018; 22 (6): 1686-1692

DOI: 10.26355/eurrev_201803_14581

lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients

Y. Liao, S. Cheng, J. Xiang, C. Luo

Department of Respiration, University-Town Hospital of Chongqing Medical University, Chongqing, China. Luochun-1@163.com


OBJECTIVE: Lung cancer is common cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. Thus, we studied whether long non-coding RNAs influence malignancy in NSCLC to discover new therapeutic targets for increasing the survival rate of NSCLC patients. lncRNA has been proven to be important in different cancer progression. In this study, we mainly focused on the role of lncRNA CCHE1 (cervical carcinoma high expressed 1) expressed PCNA regulatory lncRNA in NSCLC cancer.

PATIENTS AND METHODS: qRT-PCR was used to detect the expression of CCHE1 in 126 cases of NSCLC tissue and adjacent tissue, and the clinical significance was also analyzed. Cell Counting Kit-8 (CCK8) assay was used to detect the proliferation ability of NSCLC cancer cell lines, and Western-blot was used to measure the expression of the protein when the expression of CCHE1 was suppressed.

RESULTS: We found that the CCHE1 was highly expressed in the NSCLC tissue, compared with the adjacent tissue. We also found that the expression of CCHE1 was closely related to the size and survival time of patients. Moreover, CCHE1 could promote the proliferation, metastasis, and invasion of NSCLC cell line via increasing the expression of ERK/MAPK signaling pathway.

CONCLUSIONS: According to the results, we found that CCHE1 was closely related the progression of NSCLC, which could be a potential target for treating NSCLC.

Free PDF Download

To cite this article

Y. Liao, S. Cheng, J. Xiang, C. Luo
lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 6
Pages: 1686-1692
DOI: 10.26355/eurrev_201803_14581